AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis (vol 156, pg 769, 2019)

被引：0
|
作者：
Singh, S.
Feuerstein, J. D.
Binion, D. G.
机构：
来源：
GASTROENTEROLOGY | 2019年 / 157卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：903 / 903
页数：1
相关论文
共 50 条
  • [41] Evaluating induction and maintenance treatment with MMX mesalazine for patients with mild-to-moderate ulcerative colitis
    Solomon, D.
    Abhyankar, B.
    Barrett, K.
    Karlstadt, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 : A90 - A90
  • [42] Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis
    Horst, Sara N.
    Kane, Sunanda
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (15) : 2225 - 2232
  • [43] Mild-to-moderate ulcerative colitis: Your role in patient compliance and health care costs
    Tindall, William N.
    Boltri, John M.
    Wilhelm, Sheila M.
    JOURNAL OF MANAGED CARE PHARMACY, 2007, 13 (07): : S2 - S12
  • [44] Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis
    Ma, Christopher
    Jeyarajah, Jenny
    Guizzetti, Leonardo
    Parker, Claire E.
    Singh, Siddharth
    Dulai, Parambir S.
    D'Haens, Geert R.
    Sandborn, William J.
    Feagan, Brian G.
    Jairath, Vipul
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (02) : 447 - +
  • [45] Time to initial symptom resolution with MMX™ mesalamine therapy for active, mild-to-moderate ulcerative colitis
    Sandborn, William J.
    Karlstadt, Robyn
    Barrett, Karen
    Joseph, Raymond E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S462 - S463
  • [46] Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
    Louis, Edouard
    Paridaens, Kristine
    Al Awadhi, Sameer
    Begun, Jakob
    Cheon, Jae Hee
    Dignass, Axel U.
    Magro, Fernando
    Marquez, Juan Ricardo
    Moschen, Alexander R.
    Narula, Neeraj
    Rydzewska, Grazyna
    Freddi, Matthew J.
    Travis, Simon Pl
    BMJ OPEN GASTROENTEROLOGY, 2022, 9 (01):
  • [47] Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis
    Pruitt, R
    Hanson, J
    Safdi, M
    Wruble, L
    Hardi, R
    Johanson, J
    Koval, G
    Riff, D
    Winston, B
    Cross, A
    Doty, P
    Johnson, LK
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (12): : 3078 - 3086
  • [48] Symptomatic resolution is an inadequate predictor of complete colonic mucosal healing in mild-to-moderate ulcerative colitis
    Kornbluth, Asher
    Kamm, Michael A.
    Lichtenstein, Gary R.
    Sandborn, William J.
    Barrett, Karen
    Lees, Kirstin H.
    Joseph, Raymond E.
    GASTROENTEROLOGY, 2007, 132 (04) : A506 - A506
  • [49] AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis
    Singh, Siddharth
    Loftus Jr, Edward, V
    Limketkai, Berkeley N.
    Haydek, John P.
    Agrawal, Manasi
    Scott, Frank I.
    Ananthakrishnan, Ashwin N.
    GASTROENTEROLOGY, 2024, 167 (07) : 1307 - 1343
  • [50] Segmental Endoscopic Evaluation of Combined Oral and Topical Mesalazine (Pentasa®) in Patients With Mild-to-Moderate Ulcerative Colitis
    Suzuki, Yasuo
    Inou, Soetsu
    Uchiyama, Kan
    Kato, Masahisa
    Matsuo, Keigo
    Nakagawa, Tomoo
    Kato, Kazuki
    Kishikawa, Hiroshi
    Kimura, Norio
    GASTROENTEROLOGY, 2012, 142 (05) : S655 - S655
12345